CytomX Therapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +81.6% | +85.8% | -24.9% | +175.9% | +12.1% | -47.6% | +50.4% | -41.4% | -8.3% | +157.0% | -69.4% | +18.9% | -22.7% | +499.0% | -66.5% | +7.1% | -8.0% | -2.5% | +2.0% | +8.0% | +12.2% | -54.2% | +42.2% | -13.3% | +80.5% | +16.8% | +5.2% | +6.7% | +0.8% | +55.8% | -39.4% | +33.1% | +13.9% | +33.7% | -63.4% | -68.0% | -88.9% | +1,447.2% | -86.2% | – | |
| – | +11.6% | -0.7% | +69.9% | -28.9% | +16.4% | +5.3% | +16.1% | +3.1% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +2.1% | +0.3% | +0.5% | +2.4% | -6.9% | -65.9% | -3.9% | -1.7% | – | – | – | – | – | – | -50.8% | – | – | |
| – | +81.6% | +85.8% | -24.9% | +175.9% | +12.1% | -47.6% | +50.4% | -41.4% | -8.3% | +157.0% | -69.4% | +18.9% | -22.7% | +499.0% | -66.5% | +7.1% | -8.0% | -2.5% | +2.0% | +8.0% | +3.7% | -50.4% | +42.2% | -24.8% | +108.3% | +9.3% | +5.4% | +7.6% | +6.6% | +55.8% | -39.4% | +33.1% | +13.9% | +33.7% | -63.4% | -68.0% | -88.9% | +1,409.4% | -85.8% | – | |
| – | +15.1% | -5.0% | +92.6% | +3.0% | -28.4% | +8.5% | +13.8% | +7.8% | +2.7% | +28.5% | -15.2% | -9.3% | +30.3% | +17.5% | -43.8% | -0.1% | -8.5% | +1.7% | +16.7% | +11.7% | +23.3% | -15.0% | +2.0% | -4.4% | -34.3% | +5.4% | -2.5% | -48.1% | +85.9% | +13.8% | +14.1% | -15.1% | -30.8% | +27.6% | -29.4% | +14.9% | +38.8% | -9.4% | -8.5% | – | |
| – | +2.4% | +10.4% | +6.3% | +3.3% | +21.9% | -3.4% | +22.9% | -10.0% | +10.3% | +7.8% | -2.7% | -10.1% | +8.9% | +3.9% | -9.3% | -0.5% | +5.9% | +0.9% | +1.8% | +18.0% | -14.7% | +11.5% | +11.4% | -10.7% | -26.9% | +4.0% | -7.2% | -7.9% | +14.9% | -0.9% | +8.3% | -5.3% | -29.3% | +67.6% | -29.8% | -2.9% | +14.5% | +45.3% | -28.9% | – | |
| – | +11.6% | -1.1% | +68.4% | +3.1% | -19.5% | +5.3% | +16.0% | +3.2% | +4.5% | +23.5% | -12.6% | -9.5% | +25.3% | +14.7% | -37.5% | -0.2% | -4.7% | +1.4% | +12.3% | +13.3% | +10.7% | -7.7% | +4.4% | -8.2% | -24.7% | -6.7% | -4.0% | -47.8% | +96.3% | +9.5% | +12.6% | -12.6% | -30.4% | +38.6% | -29.5% | +9.0% | +31.6% | +3.8% | -15.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -105.5% | – | -172.5% | – | +330.0% | +28.0% | -105.7% | – | – | – | – | – | |
| – | -19.3% | -47.0% | +73.3% | +125.8% | -74.4% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +285.3% | +135.1% | +122.7% | +70.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -14,352.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -67.2% | +626.1% | -146.8% | – | +226.7% | +24.5% | -100.4% | – | – | – | – | – | |
| – | -2,700.0% | – | – | -173.1% | – | – | +63.1% | +39.7% | +256.2% | -100.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -62.1% | -95.4% | +4.1% | +19.6% | +1.6% | +0.0% | +1.6% | -7.9% | -6.9% | +9.3% | +1.7% | – | |
| – | – | – | – | – | – | -2,594.8% | – | – | – | – | – | – | – | – | -228.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -72.0% | +1,547.7% | -147.4% | – | +229.1% | +24.6% | -100.7% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +1,527.2% | -67.0% | +498.1% | -142.1% | – | +210.8% | +23.9% | -98.9% | -5,583.2% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.